期刊文献+

RP-HPLC法检查丁酸氯维地平原料药中的有关物质 被引量:2

Determination of Related Substances in Clevidipine Butyrate Drug Substance by RP-HPLC
原文传递
导出
摘要 目的:建立检查丁酸氯维地平原料药中有关物质含量的方法。方法:采用反相高效液相色谱法。色谱柱为Waters Symmetry ShieldTM,流动相为磷酸二氢钠水溶液与乙腈,采用梯度洗脱,流速为1.2 ml/min,检测波长为220 nm,进样量为20μl,柱温为35℃。分别采用不加及加校正因子的主成分自身对照法计算3批样品中6种及1种已知杂质(杂质B、C、D、E、F、G及H)的量。结果:7种杂质在各自的检测质量浓度范围内线性关系良好(r为0.997~1.000);回收率为94.96%~97.79%(RSD小于4.7%,n=3);丁酸氯维地平检测限为5 ng,杂质B^H的定量限依次为4、4、8、8、4、8、8 ng;3批样品中均未检出杂质B、C、D,总杂质量小于0.12%。结论:建立的方法简便、灵敏、准确,可用于丁酸氯维地平原料药中有关物质的检查。 OBJECTIVE: To develop the method for the content determination of related substances in clevidipine butyrate drug substance. METHODS: RP-HPLC method was adopted. The determination was performed on Waters Symmetry ShieldTM column with mobile phase consisted of sodium dihydrogen phosphate solution-acetonitrile (gradient elution) at the flow rate of 1.2 ml/min. The determination wavelength was set at 220 nm, and sample size was 20 μl. The column temperature was 35℃. The contents of 6 and 1 kinds of known impurities (impurity B, C, D, E, F, G and H) in 3 batches of samples were calculated by main component self-compare without or with calibration factor. RESULTS: 7 kinds of impurity from clevidipine butyrate revealed good linearity (r=0.997-1.000); average recoveries were 94.96%-97.79% (RSD〈4.7%, n=3). The lowest detection limit of clevidipine butyrate was 5 ng, and the limits of quantity of impurities B-H were 4, 4, 8, 8, 4, 8 and 8 ng, respectively. Impurities B, C and D were not found in 3 batches of samples, and total amount of impurity was lower than 0.12%. CONCLUSIONS: Established method is simple, sensitive and accurate, and can be used for the determination of related substances in clevidipine butyrate.
出处 《中国药房》 CAS CSCD 2014年第45期4287-4290,共4页 China Pharmacy
关键词 丁酸氯维地平 有关物质 反相高效液相色谱法 Clevidipine butyrate Related substance RP-HPLC
  • 相关文献

参考文献7

二级参考文献52

  • 1张婧,纪宪勇,孙翔,王杰.氯维地平的合成[J].中国医药工业杂志,2011,42(7):484-486. 被引量:4
  • 2徐云根,华维一,赵金慧,陈玉英,杨清华.非洛地平成品中杂质的分析和合成[J].中国药科大学学报,1995,26(2):65-67. 被引量:5
  • 3吴良法.反相高效液相色谱法测定伏立康唑的含量[J].中国药房,2007,18(1):58-59. 被引量:4
  • 4昌盛,董金华.伏立康唑(voriconazole)[J].中国药物化学杂志,2007,17(3):197-197. 被引量:3
  • 5尚茂林.抗真菌新药——伏立康唑[J].中国药房,2007,18(19):1505-1507. 被引量:13
  • 6Grodman A H, Vivas Y. New therapeutic perspectives with clevidipine., an ultra-short-acting intravenous Ca^2+ channel blocker [J]. Expert Opin Investig Drugs, 2007, 16 (9): 1449-1457.
  • 7Sorbera L A, Castaner J. Clevidipine: treatm ent of hypertension calcium channel blocker [J]. Drugs Future, 2004, 29(2): 105-111.
  • 8Suh J J, Hong Y H. Synthesis of 1,4-dihydropyridine carboxylic acids (II) [J]. Yakhak Hoechi, 1989, 33(4): 219-225.
  • 9Yang Bo(杨波),Sun Hua-jun(孙华君),Huang Lu(黄璐).et al.Crystal form of clevidipine butyrate(丁酸氯维地平的晶型):中国,CN101768105A[P].2010-01-19.
  • 10Aronson S,Dyke C M,Stierer K A,et al.The ECLIPSE trials:comparative studies of clevidipine to nitroglycerin,sodium nitroprusside,and nicardipine for acute hypertension treatment in cardiac surgery patients[J].Anesthesia & Analgesia,2008,107(4):1 110-1 121.

共引文献27

同被引文献22

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部